Slides

Back to Basics Slide Deck Resource

What is Lp(a)? Slide Deck

What is Lipoprotein(a)?

Download slides >>

Lipoprotein(a): A new causal risk factor for ASCVD and aortic valve stenosis

Lipoprotein(a): A new causal risk factor for ASCVD and aortic valve stenosis

Download slides >>

Trial slide resources: Muvalaplin

Muvalaplin in healthy volunteers (NCT04472676, Completed)

Download slides >>

Muvalaplin in high-risk patients (KRAKEN, NCT05563246, Completed)

Download slides >>

Trial slide resources: Lepodisiran

A study of lepodisiran in healthy volunteers (NCT04914546, Completed)

Download slides >>

Phase 2 study of effects of lepodisiran on elevated Lp(a) (ALPACA, NCT05565742, Completed)

Download slides >>

Phase 3 cardiovascular outcomes study of lepodisiran (ACCLAIM-Lp(a), NCT06292013, Ongoing)

Download slides >>

Trial slide resources: Olpasiran

Phase 2 dose finding study of olpasiran (OCEAN(a)-DOSE, NCT04270760, Completed)

Download slides >>

Phase 3 cardiovascular outcomes study with olpasiran (OCEAN(a)-Outcomes, NCT05581303, Ongoing)

Download slides >>

Trial slide resources: Pelacarsen

Lp(a)FRONTIERS APHERESIS (NCT05305664, Completed)

Download slides >>

Phase 2 dose ranging study of pelacarsen (NCT03070782, Completed)

Download slides >>

Phase 2 study of pelacarsen andcalcific aortic valve stenosis (NCT05646381, Ongoing)

Download slides >>

Phase 3 cardiovascular outcomes study of pelacarsen (Lp(a)HORIZON, NCT04023552, Ongoing)

Download slides >>

Trial slide resources: Zerlasiran

Phase 1 study of zerlasiran in participants with elevated Lp(a) levels (APOLLO, NCT04606602, Completed)

Download slides >>

Phase 2 study of zerlasiran to reduce Lp(a) levels (ALPACAR-360, NCT05537571, Completed)

Download slides >>

Educational Partners and Supporters